Effects of telmisartan on TNFα induced PPARγ phosphorylation and insulin resistance in adipocytes

Journal Article · Sat Sep 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2018.08.091· OSTI ID:23134241

Fang, Tao; Di, Yanbo ^[1]; Li, Guangkuo ^[2]; Cui, Xiaoxu; Shen, Na ^[1]; Li, Yonghui; Xi, Peiqi ^[2]; Xie, Yun ^[3]; Tian, Fengshi ^[2]; Li, Guangwei ^[4]

---

1. Central Laboratory, Tianjin 4th Center Hospital, Tianjin, 300140 (China)
2. Department of Cardiology, Tianjin 4th Center Hospital, Tianjin, 300140 (China)
3. Department of Neurology, Metabolic Disease Hospital of Tianjin Medical University, Tianjin, 300070 (China)
4. Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, 100037 (China)

Highlights: • Telmisartan treatment alleviates insulin resistance in adipocytes stimulated with TNFα. • Telmisartan treatment reduces phosphorylation of PPARγ in adipocytes stimulated with TNFα. • Telmisartan treatment regulates the expressions of PPARγ downstream genes. • Telmisartan treatment promotes the secretion of adiponectin in adipocytes. Telmisartan is an angiotensin II receptor blocker (ARB) and a partial agonist of peroxisome proliferator activated receptor γ (PPARγ). It has been shown to significantly enhance insulin sensitivity in clinical studies and in vitro experiments. However, the effect of telmisartan on PPARγ in adipocytes remains unknown.

• OSTI ID: 23134241
• Journal Information: Biochemical and Biophysical Research Communications, Vol. 503, Issue 4; Other Information: Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ANGIOTENSIN
INSULIN
PHOSPHORYLATION
RECEPTORS